Beijing Xuanjingrui Pharmaceutical Technology

Beijing Xuanjingrui Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the discovery and development of innovative small molecule therapeutics for central nervous system (CNS) disorders. The company's primary focus is on neurodegenerative diseases, with its lead candidate, XJR-001, being developed as a highly selective adenosine A2A receptor antagonist for Parkinson's disease. Xuanjingrui leverages its deep expertise in medicinal chemistry to design drug candidates with optimized pharmacokinetic profiles and high target selectivity. The company has successfully advanced its lead program into Phase 2 clinical trials in China, aiming to address significant unmet needs in the management of motor symptoms. Backed by prominent venture capital firms, Xuanjingrui continues to expand its pipeline into other neurological and psychiatric indications.